Importantly, biomarkers such as PD-L1 expression levels, microsatellite instability (MSI) status, and tumor mutational burden (TMB) have emerged as predictive indicators of response and are increasingly incorporated into therapeutic decision-making [74]. The gene discussed is CD274; the disease is neoplasm.